Pfizer’s Sutent gets boost in new urology guidelines
Pfizer has been boosted by news concerning its targeted cancer therapy Sutent (sunitinib malate). The orally-administered small molecule tyrosine kinase inhibitor is now recommended in new European Association of Urology guidelines, released during
by Olwen Gynn-Owen
https://www.pharmatimes.com/news/pfizers_sutent_gets_boost_in_new_urology_guidelines_989597